Financial Partners Group Inc raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 38.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,022 shares of the company’s stock after purchasing an additional 559 shares during the period. Financial Partners Group Inc’s holdings in Johnson & Johnson were worth $301,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Morgan Stanley grew its holdings in shares of Johnson & Johnson by 0.3% during the first quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock worth $2,727,694,000 after buying an additional 54,563 shares in the last quarter. Vantage Investment Partners LLC increased its holdings in Johnson & Johnson by 6.1% in the second quarter. Vantage Investment Partners LLC now owns 65,444 shares of the company’s stock valued at $9,203,000 after purchasing an additional 3,770 shares during the period. Somerville Kurt F increased its holdings in Johnson & Johnson by 3.0% in the second quarter. Somerville Kurt F now owns 131,710 shares of the company’s stock valued at $18,524,000 after purchasing an additional 3,785 shares during the period. Fundamentun LLC increased its holdings in Johnson & Johnson by 21.6% in the second quarter. Fundamentun LLC now owns 29,771 shares of the company’s stock valued at $4,187,000 after purchasing an additional 5,286 shares during the period. Finally, Ironwood Financial llc increased its holdings in Johnson & Johnson by 20.2% in the second quarter. Ironwood Financial llc now owns 446 shares of the company’s stock valued at $63,000 after purchasing an additional 75 shares during the period. Institutional investors and hedge funds own 67.44% of the company’s stock.
In related news, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.27% of the stock is currently owned by company insiders.
A number of analysts recently weighed in on JNJ shares. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research report on Wednesday, October 14th. Cantor Fitzgerald upped their price target on shares of Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, October 14th. Raymond James reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Friday, November 20th. Finally, Stifel Nicolaus cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $164.93.
JNJ stock opened at $144.68 on Tuesday. The stock has a market capitalization of $380.88 billion, a PE ratio of 22.75, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69. The company’s 50-day moving average is $144.85 and its 200-day moving average is $146.39. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The company had revenue of $21.08 billion for the quarter, compared to analysts’ expectations of $20.15 billion. During the same quarter in the prior year, the firm earned $2.12 EPS. The business’s revenue was up 1.7% on a year-over-year basis. On average, analysts anticipate that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a $1.01 dividend. The ex-dividend date is Monday, November 23rd. This represents a $4.04 annualized dividend and a yield of 2.79%. Johnson & Johnson’s payout ratio is 46.54%.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Recommended Story: How Investors Use a Balance Sheet
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.